QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Clinical trial NCT07025239 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07025239
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Colorectal Cancer

Start date: 2025-07-01
Primary completion: 2028-07-01
Enrollment: 430

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.